BUFFALO, N.Y., February 25, 2026
University at Buffalo (UB) health sciences programs delivered impressive showings in the latest Blue Ridge Institute for Medical Research (BRIMR) national rankings, reflecting strong federal research investment and a deep commitment to advancing biomedical science and clinical innovation. The rankings, which measure total funding received from the National Institutes of Health (NIH), highlighted multiple UB schools and departments for competitive performance across medicine, pharmacy, public health, and basic science disciplines, signaling a strengthening research ecosystem with broad implications for translational science and future therapeutic development.
Federal NIH Funding Boosts UB Research Capacity
In the fiscal year 2025 BRIMR report, the Jacobs School of Medicine and Biomedical Sciences secured significant NIH support, elevating its national rank to 77th among all U.S. medical schools, an improvement of four spots from 2024 and its best result in more than two decades with $49.3 million in research funding. The School of Dental Medicine placed 13th with roughly $7 million, while the School of Pharmacy and Pharmaceutical Sciences ranked 25th with just over $7 million in NIH awards. Alongside these core programs, the School of Public Health and Health Professions climbed eight places to No. 33 with $7.4 million, and the School of Nursing moved up 17 spots to No. 38 with $1.7 million in NIH support.
These rankings extend beyond traditional degree programs to include performance by individual basic and clinical science departments. Among departments ranked within the top 50 nationally were Biomedical Engineering (12th) – a joint unit between the Jacobs School and the School of Engineering and Applied Sciences – as well as Ophthalmology (36th), Physiology (38th), Emergency Medicine (39th), and Biochemistry (45th). These results underscore UB’s multi-disciplinary research strength across foundational science and clinical translation efforts.
Implications for Clinical and Translational Research
Advertisement
While this announcement is framed as a university recognition story, it has clear implications for the broader life sciences and healthcare innovation landscape. NIH funding is a critical enabler of early-stage discovery, mechanistic research, and preparatory work for clinical trial design, laying the groundwork for future FDA-regulated therapies and biomedical breakthroughs. The strong performance of UB’s pharmacology, emergency medicine, biochemistry, and biomedical engineering departments suggests a robust infrastructure for research that may eventually contribute to improved therapeutic strategies, diagnostic technologies, and evidence-based clinical practices.
The rise in NIH investment emphasizes the importance of sustained federal support for research institutions that train the next generation of scientists and clinicians. High NIH funding levels often correlate with increased peer-reviewed research output, collaborative projects across disciplines, and traction in competitive grant portfolios that can lead to new interventions for disease prevention and treatment. For universities like UB, climbing NIH rankings enhances visibility among academic partners, biotech collaborators, and translational research funders seeking sites with strong research capacity and clinical expertise.
Broader Strategic Research Growth
UB’s performance in these rankings reflects a broader institutional strategy to build scientific excellence across health sciences and synergistic engineering efforts. The inclusion of departments such as biomedical engineering, physiology, and biochemistry in the top tiers demonstrates an integrated research environment capable of addressing complex biological questions and translating findings into practical health solutions. Moreover, improvements in public health and nursing rankings underscore a commitment to both clinical research and community-level health impact, with NIH funding supporting work that spans from bench science to population health insights.
These results also serve as an indicator to prospective students, researchers, and funding agencies that UB is a growing hub for cutting-edge biomedical investigation. As research programs continue to compete for NIH awards and collaborate with external partners, the potential for breakthroughs in areas such as drug discovery, precision medicine, and health systems innovation is strengthened. For stakeholders across the academic and corporate spectrum, strong NIH funding rankings signal a thriving research culture with the capacity to contribute significantly to future scientific advancements.
Source: University at Buffalo Office of Communications press release
